Prothena Corp (PRTA): Fair Value Consensus
Prothena Corporation (PRTA) is striving to develop drugs against neuronal degradation, where success is determined by test results and patent protection. Revenues are based on payments from major partners for amyloid pathology therapies, and the metric stands at 21.45. This chart of share prices on GURU.Markets demonstrates the asset's price action. High scientific authority and alliances with industry behemoths strengthen confidence in the company's platform.
Analytical breakdowns for Prothena Corporation plc (PRTA)
- share price and expert price forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- business debt structure and liquidity details:
Debt to Equity Ratio Prothena Corporation|PRTA - Long-Term Debt to Capital|Current Liabilities to Capital Prothena Corporation PLC|PRTA - Company Total Debt|Debts to Book Capitalization Prothena Corp|PRTA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Prothena|Immediate Liquidity prothena.com
- earnings and market ratios statistics:
PRTA - Company Net Income|Forward Earnings Prothena Corporation|PRTA - Price to Earnings Ratio|Future Price to Earnings Multiple Prothena Corporation|PRTA - Price/Earnings to Growth Ratio|Company Value to EBITDA Prothena Corp|PRTA - Operating profit before deduction of amortization|Earnings per share for the last four quarters Prothena|PRTA - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months prothena.com|PRTA - Earnings growth in current year|Expected net earnings per share growth next year Prothena Corporation
Summary company analytics:PRTA Prothena Biosciences
Prothena Corporation (PRTA) development of innovative methods to combat protein aggregation in Alzheimer's and Parkinson's diseases determines the high strategic value of its intellectual capital. The average market price target consolidates leading analysts' forecasts on the business's fair value, allowing investors to compare the current price with fundamental potential and determine the quotes' margin of safety.
Competitors of Prothena Corporation
BIIB: Forecast Levels Chart|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Fair Value Consensus RGC|AXSM: Consensus Target|ACADIA Corp - Analyst Forecast Prices|XENE: Analyst Consensus Forecast|vikingtherapeutics.com (VKTX) - Analyst Consensus Forecast|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Alector Inc.|annexonbio.com - Forecast Levels Chart|Price Target Chart Omeros Corporation (OMER)|NGNE (Neurogene Inc) - Fair Value Consensus|Price Target Chart AC Immune Corp ACIU|Voyager Corp (VYGR) - Average Forecast Price|NMRA: Consensus Target|scilexholding.com - Analyst Forecast Prices|TVGN: Analyst Consensus Forecast|Alpha Cognition Inc. - Fair Value Consensus|CGTX (Cognition Therapeutics) - Analyst Consensus Forecast|Average Forecast Price Inhibikase Pharma IKT|Price Target Chart Cassava Sciences, Inc. (SAVA)|assertiotx.com - Broker Consensus Forecast|Analyst Consensus Forecast COYA (Coya Therapeutics)|Analyst Consensus Forecast VistaGen Therapeutics, Inc. VTGN|OVID: Consensus Target|Fair Value Consensus ABOS (Acumen Pharmaceuticals, Inc)|CRVO: Analyst Consensus Forecast|Consensus Target Alterity Therapeutics Limited|Price Target Chart Clene Inc|Average Forecast Price PepGen Corp PEPG|Price Target Chart Jupiter Neurosciences Inc (JUNS)|RLMD (Relmada Corp) - Fair Value Consensus|Price Target Chart Annovis Bio, Inc. ANVS|GRCE (Grace Therapeutics Inc) - Forecast Levels Chart|AIFF - Price Target Chart|Average Forecast Price Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Price Target Chart|Reviva Pharmaceuticals, Inc. - Fair Value Consensus|MTVA (MetaVia Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast neuraxis.com|Consensus Target HSDT (Helius Medical)|Analyst Forecast Prices PASG|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|Analyst Median Target Minerva (NERV)|ATHA - Price Target Chart|Average Forecast Price addextherapeutics.com|alzamend.com (ALZN) - Price Target Chart|Broker Consensus Forecast CYCN|Price Target Chart Protagenic Therapeutics Inc.|Pasithea - Forecast Levels Chart|Price Target Chart Cortigent, Inc. (CRGT)|ATXI (avenuetx.com) - Fair Value Consensus|BrainStorm Cell Therapeutics - Consensus Target|Analyst Forecast Prices CARA (Cara Therapeutics Inc.)|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|ELYM - Analyst Consensus Forecast|intracellulartherapies.com (ITCI) - Price Target Chart|Broker Consensus Forecast LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Average Forecast Price NKGen Biotech Inc NKGN|Consensus Target NRBO (NeuroBo)|Analyst Consensus Forecast Sage Therapeutics Inc (SAGE)|Price Target Chart Synaptogenix, Inc. SNPX|Fair Value Consensus TRVN|VIGL - Price Target Chart|Average Forecast Price Anew Medical Inc.|Cerevel (CERE) - Price Target Chart
